한글목차

대형 분자 의약품 원료 CDMO 시장 규모는 2025년 228억 8,000만 달러에서 2034년에는 533억 7,000만 달러에 달할 것으로 예측되고 있으며, 2026-2034년에 CAGR 9.87%로 성장할 전망입니다.

대형 분자 의약품 원료의약품 위탁개발생산기관(CDMO) 시장은 생물제제의 복잡화와 혁신적 치료법에 대한 수요 증가를 배경으로 큰 폭의 성장이 예상됩니다. 제약기업이 생물제제에 집중하는 가운데, 전문적인 제조 능력의 필요성이 매우 중요해지고 있습니다. 본 시장은 기존의 소분자 의약품에서 단클론 항체, 재조합 단백질, 유전자 치료제를 포함한 거대 분자 치료제로의 전환이 특징입니다. 이러한 제품의 복잡한 특성은 첨단 제조 공정, 엄격한 품질관리, 규제 준수를 요구하지만 CDMO는 이 분야에서 독보적인 강점을 발휘합니다.

또한 맞춤형 의료의 부상으로 맞춤형 생물제제 요법에 대한 수요가 증가하면서 고분자 의약품 원료의약품 CDMO 시장의 성장을 더욱 가속화하고 있습니다. 헬스케어 시스템이 점점 더 정밀의료 접근법을 채택하는 가운데, 맞춤형 생물제제를 대규모로 생산할 수 있는 능력은 제약기업에게 중요한 차별화 요소가 될 것입니다. 일회용 시스템이나 연속 생산과 같은 첨단 기술에 투자하는 CDMO는 경쟁 우위를 확보할 가능성이 높습니다. 또한 바이오 제약회사와 CDMO 간의 전략적 제휴는 혁신을 촉진하고 새로운 치료법 개발을 가속화하며, 시장이 역동적으로 유지되고 새로운 의료 수요에 신속하게 대응할 수 있도록 보장합니다.

대형 분자 의약품 원료의약품 CDMO의 세계 동향은 규제 상황의 발전과 지속가능성에 대한 관심 증가에 영향을 받고 있습니다. 규제 당국이 생물제제 승인 절차를 효율화함에 따라 새로운 치료제 시장 출시 시간이 단축되고 CDMO가 보다 민첩하게 대응할 수 있는 환경이 조성되고 있습니다. 또한 제조 공정에 지속가능한 관행을 통합하는 것은 규제 요건을 충족시킬 뿐만 아니라 환경 친화적인 헬스케어 솔루션에 대한 소비자 증가하는 수요와도 일치합니다. 시장이 진화하는 가운데 혁신, 협업, 지속가능성을 우선시하는 CDMO는 급성장하는 이 분야에서 성공을 거둘 수 있는 좋은 위치에 서게 될 것입니다.

목차

제1장 서론

제2장 개요

제3장 시장 변수, 동향, 프레임워크

제4장 세계의 대형 분자 의약품 원료 CDMO 시장 : 서비스별

제5장 세계의 대형 분자 의약품 원료 CDMO 시장 : 소스별

제6장 세계의 대형 분자 의약품 원료 CDMO 시장 : 최종사용자별

제7장 세계의 대형 분자 의약품 원료 CDMO 시장 : 지역별

제8장 경쟁 구도

제9장 기업 개요

영문목차

The Large Molecule Drug Substance CDMO Market size is expected to reach USD 53.37 Billion in 2034 from USD 22.88 Billion (2025) growing at a CAGR of 9.87% during 2026-2034.

The Large Molecule Drug Substance Contract Development and Manufacturing Organization (CDMO) market is poised for significant expansion, driven by the increasing complexity of biologics and the growing demand for innovative therapies. As pharmaceutical companies pivot towards biologics, the need for specialized manufacturing capabilities becomes paramount. This market is characterized by a shift from traditional small-molecule drugs to large-molecule therapeutics, including monoclonal antibodies, recombinant proteins, and gene therapies. The intricate nature of these products necessitates advanced manufacturing processes, stringent quality control, and regulatory compliance, which CDMOs are uniquely positioned to provide.

Moreover, the rise of personalized medicine is catalyzing the demand for tailored biologic therapies, further propelling the growth of the Large Molecule Drug Substance CDMO market. As healthcare systems increasingly adopt precision medicine approaches, the ability to produce customized biologics at scale will be a critical differentiator for pharmaceutical companies. CDMOs that invest in cutting-edge technologies, such as single-use systems and continuous manufacturing, will likely gain a competitive edge. Additionally, strategic partnerships between biopharmaceutical companies and CDMOs will enhance innovation and expedite the development of novel therapies, ensuring that the market remains dynamic and responsive to emerging healthcare needs.

The global landscape for Large Molecule Drug Substance CDMOs is also influenced by regulatory advancements and the increasing focus on sustainability. As regulatory bodies streamline approval processes for biologics, the time-to-market for new therapies will decrease, fostering a more agile environment for CDMOs. Furthermore, the integration of sustainable practices in manufacturing processes will not only meet regulatory requirements but also align with the growing consumer demand for environmentally responsible healthcare solutions. As the market evolves, CDMOs that prioritize innovation, collaboration, and sustainability will be well-positioned to thrive in this burgeoning sector.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Service

• Contract Manufacturing
• Contract Development

By Source

• Mammalian
• Microbial
• Others

By End-User

• Biotech Companies
• CRO
• Other

COMPANIES PROFILED

• Eurofins Scientific, WuXi Biologics, Samsung Biologics, Catalent Inc, Rentschler Biopharma SE, AGC Biologics, Recipharm AB, Siegfried Holding AG, Boehringer Ingelheim, FUJIFILM Diosynth Biotechnologies

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SERVICE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Service
• 4.2. Contract Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Contract Development Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY SOURCE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Source
• 5.2. Mammalian Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Microbial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY END-USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End-user
• 6.2. Biotech Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. CRO Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Service
  • 7.2.2 By Source
  • 7.2.3 By End-user
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Service
  • 7.3.2 By Source
  • 7.3.3 By End-user
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Service
  • 7.4.2 By Source
  • 7.4.3 By End-user
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Service
  • 7.5.2 By Source
  • 7.5.3 By End-user
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Service
  • 7.6.2 By Source
  • 7.6.3 By End-user
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL LARGE MOLECULE DRUG SUBSTANCE CDMO INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Eurofins Scientific
  • 9.2.2 WuXi Biologics
  • 9.2.3 Samsung Biologics
  • 9.2.4 Catalent Inc
  • 9.2.5 Rentschler Biopharma SE
  • 9.2.6 AGC Biologics
  • 9.2.7 Recipharm AB
  • 9.2.8 Siegfried Holding AG
  • 9.2.9 Boehringer Ingelheim
  • 9.2.10 FUJIFILM Diosynth Biotechnologies